Combined effects of obesity and type 2 diabetes contribute to increased breast cancer risk in premenopausal women by Alokail, Majed S et al.
BioMed  Central
Page 1 of 7
(page number not for citation purposes)
Cardiovascular Diabetology
Open Access Original investigation
Combined effects of obesity and type 2 diabetes contribute to 
increased breast cancer risk in premenopausal women
Majed S Alokail, Nasser M Al-Daghri*, Omar S Al-Attas and Tajamul Hussain
Address: Department of Biochemistry, College of Science, King Saud University PO Box 2455, Riyadh 11451, Kingdom of Saudi Arabia
Email: Majed S Alokail - msalokail@yahoo.com; Nasser M Al-Daghri* - nasseraldaghri@hotmail.com; Omar S Al-Attas - omrattas@ksu.edu.sa; 
Tajamul Hussain - thussain@ksu.edu.sa
* Corresponding author    
Abstract
Background: Both obesity and type 2 diabetes are among the risk factors for breast cancer
development. Combined effect of these metabolic abnormalities on breast cancer risk however,
has not been examined in premenopausal women. We tested this association in type 2 diabetic
women, categorized as obese, overweight and normal body weight groups based on BMI.
Design and methods: A total of 101 subjects were included in this study. Serum levels of IL-6,
TNF-α, C reactive protein, leptin, TGF-α, adiponectin and insulin were measured by ELISA. Data
were logarithmically transformed for variables not normally distributed. Analysis of variance with
post-hoc Bonferroni was applied to compare the data between the groups. Simple and partial
correlation coefficients between the variables were determined and a stepwise multiple linear
regression analysis was performed to determine the relationships between the variables of interest.
Results: Significantly increased levels of IL-6, C reactive protein, leptin and significantly decreased
levels of adiponectin were found in obese group, while the levels of TNF-α and TGF-α were
unaltered. A positive correlation between waist circumference and IL-6 was found in obese group.
Similarly, C reactive protein, waist and hip circumferences were linearly correlated with BMI in
obese group. Stepwise multiple linear regression analysis revealed several significant predictors for
breast cancer risk.
Conclusion:  Obesity and type 2 diabetes, owing to their effects on adipocytokines and
inflammatory mediators, contribute to increased breast cancer risk in premenopausal women. This
study emphasizes healthy life style and better management of these metabolic disorders to avoid
the pathogenesis of breast cancer and of other chronic diseases.
Background
Obesity and type 2 diabetes mellitus (T2DM) remained
major public health issues in the developed nations and
their incidence is on the rise in the developing countries,
attributed mainly to a considerable shift in the dietary
practices [1,2]. On the other hand, breast cancer is the
leading malignancy of women in industrialized nations
and its incidence as well is increasing in developing coun-
tries [3]. Genetic predisposition and environmental fac-
tors such as high fat diet and alcohol consumption
accompanied with sedentary life style constitute increased
breast cancer risk. Thus, metabolic abnormalities includ-
ing obesity and T2DM are positively associated with the
breast cancer risk [4,5]. These conditions induce changes
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in several hormonal systems, including insulin, insulin
like growth factor-1 (IGFl), estrogen, cytokines and
growth hormones. A strong association was found
between increased insulin resistance and postmenopausal
as well as premenopausal breast cancer [6,7], while the
increased estrogen levels are positively correlated with the
postmenopausal breast cancer [8].
Obesity and T2DM also have in common an altered pro-
duction of adipocytokines including leptin and adiponec-
tin [9,10]. It has been shown that increased leptin levels
and decreased adiponectin levels promote the carcinogen-
esis of the breast [11,12]. In addition, obesity is being
increasingly recognized as sub clinical inflammation and
accordingly there is an increased adipose tissue infiltra-
tion of inflammatory components including interleukin-
6 (IL-6), C-reactive protein (CRP) and tumor necrosis fac-
tor-alpha (TNF-α), which have all shown to positively
impact the breast cancer etiology [13-15]. Increased IL-6
levels in obesity can directly interfere with the insulin sig-
naling and contribute to insulin resistance [16]. IL-6 con-
trols the hepatic production of CRP, which is a risk factor
for insulin resistance, breast cancer and cardiovascular
diseases. Moreover, there is a positive correlation between
IL-6 levels and circulating CRP [17], thus increased levels
of IL-6 in obesity can directly or indirectly contribute to
the risk to develop multiple chronic diseases. CRP is pos-
itively and negatively correlated with leptin and adiponec-
tin levels respectively [18,19]. This is of special interest
because altered levels of leptin and adiponectin are con-
sistent with the elevated breast cancer risk in addition to
the independent effect of CRP in enhancing the breast
cancer risk [20]. Deletion of TNF-α or its receptor resulted
in significantly improved insulin sensitivity in both obese
mice and leptin deficient ob/ob mice [21]. In humans,
adipose tissue TNF-α expression correlated with BMI, per-
centage of body fat and hyperinsulinemia, whereas weight
loss decreased TNF-α, underlining the role of this cytokine
in obesity induced insulin resistance [22]. TNF-α and IL-6
are also shown to stimulate the breast tumor growth in
vivo [23]. Serum levels of C-peptide, a subunit of insulin
that provides a clinically useful indication of insulin pro-
duction and the degree of insulin resistance, have been
associated with an increased breast cancer risk [24]. Addi-
tionally, HDL-cholesterol, hypertension, IGF, and hyperg-
lycemia have all been found to be associated with breast
cancer risk [7,25-28]. Transforming growth factor-alpha
(TGF-α) is a member of the epidermal growth factor
(EGF) family and it induces a mitogenic response by acti-
vating the EGF receptor tyrosine kinase [29]. Overexpres-
sion of TGF-α and its cognate receptor EGF-R have been
implicated in the pathogenesis of breast cancer [30].
While majority of studies have indicated an inverse or
absence of association of T2DM or obesity with premeno-
pausal breast cancer risk, to our knowledge, none of the
studies has examined the combined effects of these meta-
bolic abnormalities in premenopausal women clinically
asymptomatic for breast cancer. We tested this association
in type 2 diabetic premenopausal women after categoriz-
ing them as normal body weight, overweight and obese
groups based on BMIs.
Methods
The subjects with T2DM were recruited from the roster of
diabetic patients attending the outpatient unit of the Dia-
betes Center, King Abdulaziz University Hospital, Riyadh,
Saudi Arabia. A total of 235 subjects were contacted for
their willingness to participate in the study. Of these, 108
subjects provided their consents. From this cohort, 7 sub-
jects were excluded from the study for the existence of
clinical complications other than T2DM to avoid the mis-
interpretation of the data. Thus, this cross sectional study
included 101 Saudi women clinically diagnosed with
T2DM. Subjects were categorized based on BMI as normal
weight, overweight and obese groups. Written and
informed consents as well as completed generalized ques-
tionnaire were obtained from all the participants prior to
their inclusion in the study. This study was conducted in
accordance with the guidelines set by the ethics commit-
tee of the King Saud University, Riyadh, Saudi Arabia.
Clinical measurements
Anthropometric measurements with emphasis to clinical
markers of adiposity were obtained. BMI was calculated
by dividing the weight (kg) with height (m2). Waist (cm)
and hip (cm) circumferences were measured and waist-to-
hip ratio was determined. Blood pressure (mm. Hg) was
measured twice after 30 minutes of rest using the conven-
tional mercurial sphygmomanometer and the values of
the readings were averaged.
Biochemical Parameters
Fasting blood glucose, and complete lipid profile (triglyc-
erides, total cholesterol, LDL- and HDL-cholesterol) were
determined using routine laboratory methods. Insulin
was analyzed by a solid phase enzyme amplified sensitiv-
ity immunoassay (Medgenix INS-ELISA, Biosource, Bel-
gium). Serum levels of leptin, TNF-α, CRP, IL-6 and
adiponectin were measured by ELISA (R&D systems, MN.
U.S.A. and Linco Research Inc, St.Charles, MO). TGF-α
was measured using immunological techniques (Linco
Research Inc, St. Charles, MO). Homeostasis model
assessment (HOMA) was applied to evaluate fasting insu-
lin resistance using the formula; glucose (mmol/L) × insu-
lin (u μl/mL)/22.5.
Statistics
SPSS version 11.5 for windows (Chicago, Illinois) was
employed for statistical analysis of the data. FrequenciesCardiovascular Diabetology 2009, 8:33 http://www.cardiab.com/content/8/1/33
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were presented in percent (%) of cases. Data was logarith-
mically transformed for variables, including insulin, TGF-
α, triglycerides, leptin, CRP, IL-6 and HOMA-IR, for not
being normally distributed. Analysis of variance with
post-hoc Bonferroni was applied to compare the data
between the groups. Simple and partial correlation coeffi-
cients between the variables were determined and a step-
wise multiple linear regression analysis was performed to
determine relationships between the variables of interest
using IL-6 as the dependent variable and all other param-
eters as independent variables. Significance was set at P-
value < 0.05.
Results and discussion
Women who were obese were significantly older and had
elevated systolic blood pressure, waist and hip circumfer-
ences (p < 0.05 respectively) as compared to women with
normal BMI (Table 1). Among the metabolic parameters,
obese women had significantly higher levels of serum lep-
tin, CRP, IL-6 (p < 0.05 respectively) and significantly
lower levels of adiponectin (p < 0.05) as compared to nor-
mal BMI group (Table 1). We found a significant positive
correlation (R = 0.296; P< 0.04) between IL-6 and waist
circumference in obese group (Figure 1C), while the cor-
relation was insignificant in normal body weight (R =
Table 1: Clinical and metabolic parameters of the subjects
Parameters Normal weight
(N = 22)
Overweight
(N = 34)
Obese
(N = 34)
Age (years) 38.38 ± 11.54 44.71 ± 6.15 44.13 ± 8.42*
BMI (kg/m2) 22.54 ± 2.34 27.73 ± 2.21* 35.76 ± 3.48
Systolic BP (mmHg) 119.86 ± 14.26 127.53 ± 29.81 130.63 ± 15.78*
Diastolic BP (mmHg) 78.76 ± 9.15 76.82 ± 10.58 82.67 ± 12.77
Waist (cm) 90.0 ± 8.98 91.45 ± 8.52 107.57 ± 10.21*
Hips (cm) 92.86 ± 7.31 97.48 ± 8.23 107.0 ± 14.24*
Glucose (mmol/L) 7.28 ± 3.4 8.49 ± 3.86 8.13 ± 4.1
Insulin (μIU/ml)# 15.19 (1.83–42.75) 16.2 (0.51–42.25) 18.82 (2.45–55.82)
HOMA-IR # 5.46 (0.33–22.23) 5.91 (0.17–14.68) 7.0 (0.19–43.66)
Total cholesterol (mmol/L) 4.93 ± 0.92 4.84 ± 1.07 4.7 ± 1.3
LDL-cholesterol (mmol/L) 2.96 ± 0.75 2.77 ± 0.71 2.81 ± 1.01
HDL-cholesterol (mmol/L) 1.26 ± 0.34 1.22 ± 0.37 1.22 ± 0.32
Triglycerides (mmol/L)# 1.33 (0.5–3.04) 1.79 (0.43–7.41) 2.01 (0.43–20.49)
Leptin (ng/ml)# 16.4 (3.2–45.90) 24.86 (1.27–77.60) 35.28 (4.04–120)*
Adiponectin (μg/ml)# 7.6 (2.39–16.90) 4.6 (1.72–9.39)* 4.7 (1.9–7.95) *
CRP (μg/ml)# 2.3 (0–13.30) 5.2 (0–205.0) 6.9 (0.07–34.20)*
TNF-α (pg/ml) 4.8 ± 1.88 4.7 ± 2.0 4.5 ± 1.6
IL-6 (pg/ml)# 4.6 (0.07–10.34) 4.9 (0.11–24.1) 8.3 (0.28–45.30)*
TGF-α (pg/ml)# 13.8 (7.9–42.34) 11.6 (7.0–28.58) 12.3 (7.9–23.01)
Data presented as mean ± SD; parameters marked # indicate median (range); * denotes significance compared to normal weight group; ¶denotes 
significance compared to normal and over weight groups. ¶*P < 0.05Cardiovascular Diabetology 2009, 8:33 http://www.cardiab.com/content/8/1/33
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0.011; P< 0.68) group as well as in overweight group (R =
0.24; P< 0.08) (Figure 1A and 1B). BMI was significantly
correlated to waist and hip circumference as well as CRP
levels in obese group and was insignificant in normal
weight as well as overweight groups (Table 2). The rest of
the associations were non-contributory.
In a stepwise multiple linear regression analysis, using IL-
6 as the dependent variable and all other parameters as
independent variables, leptin was found to be a signifi-
cant predictor among the overweight group (R = 0.75; p <
0.0001) and TGF-α, CRP and BMI for the normal weight
group (R = 0.64; p < 0.001) (Table 3). IL-6 was the sole sig-
nificant predictor for the levels of TGF-α among the nor-
mal weight group (R = 0.36; p = 0.003) (Table 3).
Adiponectin levels, hip and waist circumferences were sig-
nificant predictor of BMI in normal weight group (Table
3). In addition to these parameters, CRP was found to be
an additional predictor of BMI in obese group (Table 3).
Levels of insulin, glucose and diastolic pressure were sig-
nificant predictors of HOMA-IR in normal and obese
weight groups (Table 3), while insulin, glucose, LDL-cho-
lesterol and waist circumference were significant predic-
tors in over weight group (Table 3).
Obesity is increasingly associated with postmenopausal
breast cancer risk, whereas, in premenopausal women
there is an inverse relationship between BMI and the risk
[31,32]. However, both pre-menopausal and post meno-
pausal breast cancer patients who are obese are more
likely to have a poor final out come than those who are
non-obese [32]. It is widely accepted that the influence of
obesity on risk of breast cancer specifically applies to
upper body obesity. Consistently, increased waist to hip
ratio and waist circumference has shown to be associated
with the breast cancer risk which, importantly was slightly
diminished by controlling for the BMI [33]. This suggests
that increased waist to hip ratio and waist circumference
play critical role in the breast cancer risk than increased
BMI alone. In the present study, the significant increase in
waist and hip circumference in obese group in compari-
son to normal weight group and linear correlation
between BMI and the waist and hip circumference in the
obese group suggest that the women with increased upper
body obesity are at an increased risk for breast cancer. This
was further strengthened by the lack of significant correla-
tions between normal body weight group and overweight
group, despite a significant increase in BMI in the later.
Diabetic condition induces changes in several hormonal
systems, including insulin, insulin like growth factors,
estrogens and other cytokines that may affect the breast
cancer risk. Characteristics of T2DM including insulin
resistance and the resultant hyperinsulinemia are strongly
correlated with postmenopausal as well as pre-menopau-
sal breast cancer risk [6,7]. Hyperglycemia, which devel-
ops as a result of resistance to the action of insulin, is
positively associated with the elevated levels of glucose.
High fasting glucose levels were directly correlated with
breast cancer risk both in pre-menopausal and postmeno-
pausal women [7,34]. Studies also indicate that fasting
glucose levels ≥ 126 mg/dl, which is cutoff for defining the
T2DM were related to an increased risk for the carcinogen-
esis of the breast [34,35]. In addition, reduced HDL-cho-
lesterol and increased blood pressure have contributed to
increased risk for breast cancer [26,36]. Thus, type 2 dia-
betic status, with its multiple risk factors, appears to be an
important contributor of breast cancer risk. In our study,
though there is a lack of correlation between the breast
cancer risk factors, including cholesterol, insulin, glucose
and insulin resistance, with an increasing BMI, the pres-
ence of diabetic status in the studied subjects itself may
contribute to increased breast cancer risk. This can be
attributed to above the normal cutoff values of these
parameters in all the subjects irrespective of their BMIs; for
example, increased glucose levels in type 2 diabetics may
still pose a significant breast cancer risk in women with
the normal body weight. This might also explain a causal
relationship for the presence of breast cancer risk in the
pre-menopausal women in the present study.
Obesity and T2DM also have in common an increased pro-
duction of leptin and a decreased production of adiponec-
tin [9,10]. Such an association is consistent with a positive
impact of both obesity and T2DM on breast cancer risk
[11,12]. In addition, a linear correlation between the
plasma CRP and leptin concentrations contributes to an
enhanced breast cancer risk [18,37]. Accordingly, decreased
adiponectin levels in obese as well as overweight subjects
and increased leptin levels in obese women in this study are
Table 2: Spearman's correlation analyses using BMI as dependent variable
Normal Overweight Obese
RP - V a l u e RP - V a l u e RP - V a l u e
Waist circumference 0.04 0.90 0.25 0.17 0.39 0.01
Hip circumference 0.22 0.45 0.15 0.41 0.50 0.001
CRP 0.21 0.35 0.15 0.40 0.43 0.003
Parameters that were not included were insignificantCardiovascular Diabetology 2009, 8:33 http://www.cardiab.com/content/8/1/33
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consistent with the association of these adipocytokines
with obesity and T2DM and thus suggest increased breast
cancer risk. Presence of diabetic status, irrespective of BMI
itself indicates breast cancer risk in the studied subjects
owing to above or below the normal cutoff values of leptin
and adiponectin levels respectively. This is in agreement
with the finding that leptin levels in T2DM are positively
correlated with the degree of insulin resistance independ-
ent of BMI and body fat content [38].
Inflammation is associated with poor prognosis and
decreased survival in many cancers. Obesity per se is con-
sidered a subclinical inflammation and thus, as markers
of inflammation and their positive role in breast carcino-
genesis, the increased levels of IL-6 and CRP in obese
women in the present study are consistent with the breast
cancer risk. Importantly, in obese women, a positive cor-
relation between IL-6 and waist circumference, which
itself is an independent risk factor for breast cancer, sug-
gests obesity induced inflammatory response and
enhanced risk for carcinogenesis. In addition, CRP is pos-
itively correlated with leptin and inversely with the adi-
ponectin levels [18,19]. Thus, in obesity, the
adipocytokines and the inflammatory mediators might
Linear regression analyses between waist circumference and IL-6 Figure 1
Linear regression analyses between waist circumference and IL-6. Linear regression analyses of IL-6 and waist cir-
cumference in normal body weight, overweight and obese groups revealed a significant positive correlation (P < 0.04; R = 
0.296) in obese group.Cardiovascular Diabetology 2009, 8:33 http://www.cardiab.com/content/8/1/33
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exert an additive effect to positively impact the breast can-
cer etiology. Unaltered TNF-α in the studied subjects may
relate its dependency on the insulin as the TNF-α secre-
tion was positively correlated with the plasma insulin
concentrations [39], which is consistent with unaltered
serum insulin levels in the subjects independent of BMI.
Lack of change in TGF-α in the studied subjects may pos-
sibly indicate its association at a later stage in the disease
progression or exclusively associated with postmenopau-
sal breast cancer risk. Though, T2DM and obesity induced
breast cancer risk found in the premenopausal women in
this study may contradicts with a number of studies, while
considering that the etiological factors for breast cancer
act over a long time, menopausal transition may unlikely
have a significant impact in altering the cancer risk. Alter-
natively, factors responsible for the disease risk may differ
between pre and post-menopausal states.
We acknowledge several limitations in this study. Due to
small sample size especially in normal and overweight
groups, some of the associations might be altered if analyzed
on a larger sample size. Though, the presence of diabetic sta-
tus in the studied subjects itself was found to be a risk factor
for breast cancer in our study, we did not verify this finding
by comparing with non diabetic normal control subjects.
Additionally, conclusions made in this study were based on
the prevalence of breast cancer risk factors in obese and
T2DM subjects, while not directly evaluating these risk fac-
tors in the breast cancer patients. Due to cross sectional
nature of this study and small sample size the observations
need to be followed up with much larger sample size and in
a prospective setup to make a causal inference.
Conclusion
In summary, we found the presence of increased breast
cancer risk in obese type 2 diabetic premenopausal
women. Furthermore, altered expression of inflammatory
mediators and the adipocytokines in obese diabetic
women may collectively promote the breast cancer etiol-
ogy as compared to women with normal body weight.
Since the association of adipocytokines and inflammatory
markers with breast cancer has been firmly established,
our objective to measure these parameters in obese T2DM
subjects while not in breast cancer cases was to assess
whether the existence of these metabolic abnormalities
confers an additional risk to develop the breast cancer. In
this context, findings of this study attain significance in
predicting the breast cancer risk and avoiding its carcino-
genesis. Additionally, this study recommend a healthy life
style, regular physical activities and a healthy diet to coun-
ter the growing epidemics of obesity, T2DM and associ-
ated disorders such as breast cancer and cardiovascular
diseases.
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Table 3: Significant predictors of breast cancer risk using dependent variables of interest
Dependent Variables
Group IL-6 TGF-α BMI HOMA-IR
Normal weight TGF-α, CRP, BMI
R = 0.64;
p < 0.001
IL-6
R = 0.35
p < 0.009
Adiponectin,
Hip, waist
R = 0.88;
p < 0.001
Insulin, glucose, diastolic,
R = 0.97;
p < 0.001
Overweight Leptin,
R = 0.75;
p < 0.0001
Triglycerides
R = 0.44
P < 0.046
------ Insulin, glucose, LDL, waist
R = 0.98;
p < 0.001
Obese ------ ------ Hip, waist, CRP, adiponectin
R = 0.84;
p = < 0.001
Insulin, glucose, diastolic,
R = 0.97;
p < 0.001
Independent variables entered: BMI, waist circumference, hip circumference, WHR,
leptin, adiponectin, CRP, TNF-α, insulin, HOMA-IR, TGF-α, and IL-6Cardiovascular Diabetology 2009, 8:33 http://www.cardiab.com/content/8/1/33
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